热景生物：参股公司舜景医药的创新药SGC001注射液Ib期临床研究完成所有受试者观察并揭盲

Core Viewpoint - The announcement highlights the successful completion of Phase Ia and Ib clinical trials for the innovative drug SGC001 injection by the affiliated company ShunJing Pharmaceutical, indicating promising results for acute myocardial infarction treatment [1] Group 1: Clinical Trial Results - SGC001 injection has completed Phase Ia clinical research in healthy volunteers and Phase Ib clinical observation in patients with ST-segment elevation myocardial infarction [1] - No grade 3 or higher adverse events were reported across all dosage groups, suggesting a favorable safety profile [1] - Preliminary efficacy results align with expectations, indicating potential effectiveness for acute myocardial infarction patients [1] Group 2: Market Context - There are currently no antibody drugs for acute myocardial infarction that have entered clinical research or approval stages, positioning SGC001 as a potentially pioneering treatment in this area [1]